Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis.

Reddy PS, Legault HM, Sypek JP, Collins MJ, Goad E, Goldman SJ, Liu W, Murray S, Dorner AJ, O'Toole M.

Arthritis Res Ther. 2008;10(6):R127. doi: 10.1186/ar2541. Epub 2008 Nov 3. Erratum in: Arthritis Res Ther. 2009;11(2):407.

2.

Human alveolar macrophage gene responses to Mycobacterium tuberculosis strains H37Ra and H37Rv.

Silver RF, Walrath J, Lee H, Jacobson BA, Horton H, Bowman MR, Nocka K, Sypek JP.

Am J Respir Cell Mol Biol. 2009 Apr;40(4):491-504. doi: 10.1165/rcmb.2008-0219OC. Epub 2008 Sep 11.

3.

Gob-5 contributes to goblet cell hyperplasia and modulates pulmonary tissue inflammation.

Long AJ, Sypek JP, Askew R, Fish SC, Mason LE, Williams CM, Goldman SJ.

Am J Respir Cell Mol Biol. 2006 Sep;35(3):357-65. Epub 2006 Apr 27.

PMID:
16645179
4.

Gene expression analysis in a murine model of allergic asthma reveals overlapping disease and therapy dependent pathways in the lung.

Follettie MT, Ellis DK, Donaldson DD, Hill AA, Diesl V, DeClercq C, Sypek JP, Dorner AJ, Wills-Karp M.

Pharmacogenomics J. 2006 Mar-Apr;6(2):141-52.

PMID:
16402082
5.

Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Murray HW, Flanders KC, Donaldson DD, Sypek JP, Gotwals PJ, Liu J, Ma X.

Infect Immun. 2005 Jul;73(7):3903-11.

6.

Gene expression profiles in human nasal polyp tissues studied by means of DNA microarray.

Liu Z, Kim J, Sypek JP, Wang IM, Horton H, Oppenheim FG, Bochner BS.

J Allergy Clin Immunol. 2004 Oct;114(4):783-90.

PMID:
15480316
7.

P-selectin suppresses hepatic inflammation and fibrosis in mice by regulating interferon gamma and the IL-13 decoy receptor.

Wynn TA, Hesse M, Sandler NG, Kaviratne M, Hoffmann KF, Chiaramonte MG, Reiman R, Cheever AW, Sypek JP, Mentink-Kane MM.

Hepatology. 2004 Mar;39(3):676-87.

PMID:
14999686
8.

Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2.

Wood N, Whitters MJ, Jacobson BA, Witek J, Sypek JP, Kasaian M, Eppihimer MJ, Unger M, Tanaka T, Goldman SJ, Collins M, Donaldson DD, Grusby MJ.

J Exp Med. 2003 Mar 17;197(6):703-9.

9.

T helper differentiation in resistant and susceptible B7-deficient mice infected with Leishmania major.

Brown JA, Greenwald RJ, Scott S, Schweitzer AN, Satoskar AR, Chung C, Schopf LR, van der Woude D, Sypek JP, Sharpe AH.

Eur J Immunol. 2002 Jun;32(6):1764-72.

10.

Effects of IL-13 on airway responses in the guinea pig.

Morse B, Sypek JP, Donaldson DD, Haley KJ, Lilly CM.

Am J Physiol Lung Cell Mol Physiol. 2002 Jan;282(1):L44-9.

11.
12.

Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis.

Murray HW, Montelibano C, Peterson R, Sypek JP.

J Infect Dis. 2000 Nov;182(5):1497-502. Epub 2000 Oct 9.

PMID:
11023473
13.

Gastrointestinal nematode expulsion in IL-4 knockout mice is IL-13 dependent.

Bancroft AJ, Artis D, Donaldson DD, Sypek JP, Grencis RK.

Eur J Immunol. 2000 Jul;30(7):2083-91.

14.

Autocrine regulation of IL-12 receptor expression is independent of secondary IFN-gamma secretion and not restricted to T and NK cells.

Thibodeaux DK, Hunter SE, Waldburger KE, Bliss JL, Trepicchio WL, Sypek JP, Dunussi-Joannopoulos K, Goldman SJ, Leonard JP.

J Immunol. 1999 Nov 15;163(10):5257-64.

15.

Expression of Th2 cytokines and the stable Th2 marker ST2L in the absence of IL-4 during Leishmania major infection.

Kropf P, Schopf LR, Chung CL, Xu D, Liew FY, Sypek JP, Müller I.

Eur J Immunol. 1999 Nov;29(11):3621-8.

16.

Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis.

Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K.

J Immunol. 1999 Oct 15;163(8):4481-8.

17.
18.

The role of recombinant murine IL-12 and IFN-gamma in the pathogenesis of a murine systemic Candida albicans infection.

Lavigne LM, Schopf LR, Chung CL, Maylor R, Sypek JP.

J Immunol. 1998 Jan 1;160(1):284-92.

19.

Administration of recombinant human interleukin 12 to chronically SIVmac-infected rhesus monkeys.

Watanabe N, Sypek JP, Mittler S, Reimann KA, Flores-Villanueva P, Voss G, Lord CI, Letvin NL.

AIDS Res Hum Retroviruses. 1998 Mar 20;14(5):393-9.

PMID:
9546798
20.

Interleukin-12 promotes a chronic intestinal nematode infection.

Bancroft AJ, Else KJ, Sypek JP, Grencis RK.

Eur J Immunol. 1997 Apr;27(4):866-70.

PMID:
9130637
21.

Antiproliferative effects of interleukin-12 treatment on human tumor colony-forming units taken directly from patients.

Izquierdo MA, Degen D, Sypek JP, Von Hoff DD.

Anticancer Drugs. 1996 May;7(3):275-80.

PMID:
8792000
23.

Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response.

Sypek JP, Chung CL, Mayor SE, Subramanyam JM, Goldman SJ, Sieburth DS, Wolf SF, Schaub RG.

J Exp Med. 1993 Jun 1;177(6):1797-802.

24.
27.
28.
29.

Macrophage activation for antileishmanial defense by an apparently novel mechanism.

Wyler DJ, Beller DI, Sypek JP.

J Immunol. 1987 Feb 15;138(4):1246-9.

PMID:
3100630
31.

Antigen recognition by effector T cells in antileishmanial defense.

Sypek JP, Panosian CB, Wyler DJ.

J Infect Dis. 1985 Nov;152(5):1057-63.

PMID:
2413143
32.

In vitro parasite-monocyte interactions in human leishmaniasis: possible role of fibronectin in parasite attachment.

Wyler DJ, Sypek JP, McDonald JA.

Infect Immun. 1985 Aug;49(2):305-11. Erratum in: Infect Immun 1986 Feb;51(2):721.

35.

Supplemental Content

Loading ...
Support Center